Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T
(Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11 MUT] and KEAP1 MUT)
are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 …

The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …

Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …